1. The intranasal dexmedetomidine plus ketamine for procedural sedation in children, adaptive randomized controlled non-inferiority multicenter trial (Ketodex): a statistical analysis plan
- Author
-
Heath, Anna, Rios, Juan David, Pullenayegum, Eleanor, Pechlivanoglou, Petros, Offringa, Martin, Yaskina, Maryna, Watts, Rick, Rimmer, Shana, Klassen, Terry P., Coriolano, Kamary, Poonai, Naveen, Beer, Darcy, Sawyer, Scott, Bhatt, Maala, Kam, April, Doan, Quynh, Sabhaney, Vikram, Hickes, Serena, Ali, Samina, Stillwell, Karly, Erickson, Tannis, Bowkett, Chelsea, Shimmin, Carolyn, Foot, Brendon, McGahern, Candace, Carciurmaruj, Redjana, Schellenberg, Jeannine, and University of Manitoba
- Subjects
Statistical analysis plan ,Pediatric closed reduction ,medicine.medical_treatment ,Sedation ,Medicine (miscellaneous) ,Pediatrics ,Update ,03 medical and health sciences ,Route of administration ,0302 clinical medicine ,030225 pediatrics ,Multicenter trial ,medicine ,Humans ,Hypnotics and Sedatives ,Pharmacology (medical) ,Ketamine ,030212 general & internal medicine ,Dexmedetomidine ,Child ,Intranasal ketodex ,Adverse effect ,Non-inferiority trial ,Administration, Intranasal ,Analgesics ,lcsh:R5-920 ,business.industry ,Bayes Theorem ,Emergency department ,Bayesian adaptive design ,3. Good health ,Procedural sedation and analgesia ,Anesthesia ,medicine.symptom ,lcsh:Medicine (General) ,business ,medicine.drug - Abstract
Background Procedural sedation and analgesia (PSA) is frequently required to perform closed reductions for fractures and dislocations in children. Intravenous (IV) ketamine is the most commonly used sedative agent for closed reductions. However, as children find IV insertion a distressing and painful procedure, there is need to identify a feasible alternative route of administration. There is evidence that a combination of dexmedetomidine and ketamine (ketodex), administered intranasally (IN), could provide adequate sedation for closed reductions while avoiding the need for IV insertion. However, there is uncertainty about the optimal combination dose for the two agents and whether it can provide adequate sedation for closed reductions. The Intranasal Dexmedetomidine Plus Ketamine for Procedural Sedation (Ketodex) study is a Bayesian phase II/III, non-inferiority trial in children undergoing PSA for closed reductions that aims to address both these research questions. This article presents in detail the statistical analysis plan for the Ketodex trial and was submitted before the outcomes of the trial were available for analysis. Methods/design The Ketodex trial is a multicenter, four-armed, randomized, double-dummy controlled, Bayesian response adaptive dose finding, non-inferiority, phase II/III trial designed to determine (i) whether IN ketodex is non-inferior to IV ketamine for adequate sedation in children undergoing a closed reduction of a fracture or dislocation in a pediatric emergency department and (ii) the combination dose for IN ketodex that provides optimal sedation. Adequate sedation will be primarily measured using the Pediatric Sedation State Scale. As secondary outcomes, the Ketodex trial will compare the length of stay in the emergency department, time to wakening, and adverse events between study arms. Discussion The Ketodex trial will provide evidence on the optimal dose for, and effectiveness of, IN ketodex as an alternative to IV ketamine providing sedation for patients undergoing a closed reduction. The data from the Ketodex trial will be analyzed from a Bayesian perspective according to this statistical analysis plan. This will reduce the risk of producing data-driven results introducing bias in our reported outcomes. Trial registration ClinicalTrials.gov NCT04195256. Registered on December 11, 2019.
- Published
- 2021